Kymera Therapeutics, Inc. 8-K

What Happened

• Kymera Therapeutics, Inc. announced its financial results for the quarter and fiscal year ended December 31, 2025 by filing a Form 8-K on February 26, 2026. The company furnished a press release with the results as Exhibit 99.1 to the filing. The Form 8-K was signed by Nello Mainolfi, Ph.D., President and Chief Executive Officer.

Key Details

• Announcement date: February 26, 2026 (Form 8-K filed and press release furnished).
• Reporting period: Quarter ended December 31, 2025 and fiscal year ended December 31, 2025.
• Press release: Provided as Exhibit 99.1 to the Form 8-K (information furnished, not “filed” under Section 18 of the Exchange Act).
• Signature: Form 8-K signed by Nello Mainolfi, Ph.D., President & CEO.

Why It Matters

• This Form 8-K signals Kymera has released its latest earnings and year-end financial results; investors should review the furnished press release (Exhibit 99.1) for revenue, profit/loss, cash runway, and any operational updates.
• Because the press release is furnished (not filed), it is disclosed to the market but is not subject to Section 18 liability; investors should treat the release as the company’s official summary of quarterly and annual results and wait for any subsequent filings (e.g., 10-Q/10-K) for audited or detailed financial statements.